Literature DB >> 9698213

Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine.

Y Glinka1, K F Tipton, M B Youdim.   

Abstract

Inhibition of mitochondrial complex I by 6-hydroxydopamine was studied in brain and liver preparations. NADH-quinone reductase activity of this complex from rat brain was inhibited by 6-hydroxydopamine partially uncompetitively with respect to NADH with a value of Ki 0.051 +/- 0.014 mM. The inhibition patterns for liver NADH-quinone reductase were more complicated than those obtained with the brain enzyme. Desferrioxamine behaved as a 'competitive' activator of complex I from both liver and brain (Ka = 2 mM and 0.02 mM, respectively). It also protected brain complex I against the inhibition by increasing Ki value about 10-fold. Furthermore, in the presence of desferrioxamine the residual activity of enzyme-substrate-inhibitor complex was increased. The data suggest that desferrioxamine does not compete directly with 6-hydroxydopamine for binding to the inhibitory site, but induces a conformation which is unfavorable for the binding of the inhibitor to the protein. The qualitative and quantitative differences between the behavior of the liver and brain enzyme complexes indicate that the assumption that the behavior of liver mitochondria can be used as a model for the situation in brain should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698213     DOI: 10.1016/s0014-2999(98)00279-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease.

Authors:  Sofía Sánchez-Iglesias; Pablo Rey; Estefanía Méndez-Alvarez; José Luis Labandeira-García; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2006-12-12       Impact factor: 3.996

2.  Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase.

Authors:  Javier Iglesias-González; Sofía Sánchez-Iglesias; Estefanía Méndez-Álvarez; Sarah Rose; Atsuko Hikima; Peter Jenner; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2012-07-22       Impact factor: 3.996

Review 3.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

4.  Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease.

Authors:  Chiara Milanese; Victor Tapias; Sylvia Gabriels; Silvia Cerri; Giovanna Levandis; Fabio Blandini; Maria Tresini; Sruti Shiva; John Timothy Greenamyre; Mark T Gladwin; Pier G Mastroberardino
Journal:  Antioxid Redox Signal       Date:  2017-09-21       Impact factor: 8.401

Review 5.  Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

Authors:  A Barzilai; E Melamed; A Shirvan
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

6.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

Review 7.  Proteomic approach to studying Parkinson's disease.

Authors:  Jing Zhang; David R Goodlett
Journal:  Mol Neurobiol       Date:  2004-06       Impact factor: 5.590

8.  6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses.

Authors:  Andreas Kupsch; Werner Schmidt; Zemfira Gizatullina; Grazyna Debska-Vielhaber; Jürgen Voges; Frank Striggow; Patricia Panther; Herbert Schwegler; Hans-Jochen Heinze; Stefan Vielhaber; Frank Norbert Gellerich
Journal:  J Neural Transm (Vienna)       Date:  2014-03-14       Impact factor: 3.575

Review 9.  Behavioral Phenotyping and Pathological Indicators of Parkinson's Disease in C. elegans Models.

Authors:  Malabika Maulik; Swarup Mitra; Abel Bult-Ito; Barbara E Taylor; Elena M Vayndorf
Journal:  Front Genet       Date:  2017-06-13       Impact factor: 4.599

Review 10.  Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

Authors:  V Bogaerts; J Theuns; C van Broeckhoven
Journal:  Genes Brain Behav       Date:  2007-08-03       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.